349 related articles for article (PubMed ID: 8775469)
1. Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture.
Fracchia M; Soubrane O; Houssin D; Galatola G
Ital J Gastroenterol; 1995; 27(8):430-5. PubMed ID: 8775469
[TBL] [Abstract][Full Text] [Related]
2. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
4. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
Rudolph G; Endele R; Senn M; Stiehl A
Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
[TBL] [Abstract][Full Text] [Related]
5. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
Hay JE
Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
[TBL] [Abstract][Full Text] [Related]
6. [Drug therapy of cholestatic hepatopathies].
Leuschner U
Schweiz Rundsch Med Prax; 1992 Aug; 81(34):983-4. PubMed ID: 1529191
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer.
Linder S; Söderlund C
Hepatogastroenterology; 2001; 48(38):387-92. PubMed ID: 11379315
[TBL] [Abstract][Full Text] [Related]
8. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.
Rudolph G; Kloeters-Plachky P; Rost D; Stiehl A
Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):487-91. PubMed ID: 17489059
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for primary sclerosing cholangitis.
Sinakos E; Lindor K
Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):473-88. PubMed ID: 20678020
[TBL] [Abstract][Full Text] [Related]
10. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
11. [Prevention of clogging of biliary stents by administration of levofloxacin and ursodeoxycholic acid].
Sciumè C; Geraci G; Pisello F; Facella T; Li Volsi F; Modica G
Chir Ital; 2004; 56(6):831-7. PubMed ID: 15771038
[TBL] [Abstract][Full Text] [Related]
12. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
13. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.
Lindor KD
N Engl J Med; 1997 Mar; 336(10):691-5. PubMed ID: 9041099
[TBL] [Abstract][Full Text] [Related]
14. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies.
van Milligen de Wit AW; van Deventer SJ; Tytgat GN
Am J Gastroenterol; 1995 Jun; 90(6):893-900. PubMed ID: 7771416
[TBL] [Abstract][Full Text] [Related]
15. Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis.
Murray MD; Burton FR; Di Bisceglie AM
J Clin Gastroenterol; 2007 Jan; 41(1):115-7. PubMed ID: 17198074
[TBL] [Abstract][Full Text] [Related]
16. Primary sclerosing cholangitis.
Zein CO; Lindor KD
Semin Gastrointest Dis; 2001 Apr; 12(2):103-12. PubMed ID: 11352117
[TBL] [Abstract][Full Text] [Related]
17. Post-liver transplant cholestatic disorder with biliary strictures: de novo versus recurrent primary sclerosing cholangitis.
McPartland KJ; Lewis WD; Gordon FD; Pomfret EA; Pomposelli JJ; Jenkins R; Khettry U
Pathol Int; 2009 May; 59(5):312-6. PubMed ID: 19432673
[TBL] [Abstract][Full Text] [Related]
18. Sclerosing cholangitis.
MacFaul GR; Chapman RW
Curr Opin Gastroenterol; 2006 May; 22(3):288-93. PubMed ID: 16550044
[TBL] [Abstract][Full Text] [Related]
19. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
20. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
Wolf JM; Rybicki LA; Lashner BA
Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
